Valion Bio, Inc. — Form SCHEDULE 13D
Filed August 3, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
▼ Likely negative
significance 78/100
What the filing says
3i, LP (managing member Maier Tarlow) and affiliated entities Tumim Stone Capital and 3i Management LLC filed a Schedule 13D on August 3, 2026, demanding immediate removal of CEO Michael Handley, claiming sustained mismanagement and shareholder value destruction. Over the past 60 days, 3i, LP sold approximately 144,000 shares across May–July 2026 at prices ranging from $0.41–$1.05, while simultaneously converting 485,842 shares of Series B Preferred Stock (at conversion prices $0.38–$0.55), and threatening all available shareholder remedies if the Board does not act.
Why this rating
Forced leadership crisis at micro-cap ($4M market cap); major shareholder activist demand + heavy concurrent selling + conversion activity signals severe governance/operational distress and potential control battle. Material relative to company size.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.